Singular Genomics Systems has unveiled its Max Read Kits, designed to maximise throughput and reduce costs for single cell experiments.

Run on the company’s G4 Sequencing Platform, the Max Read Kits for single-cell applications have been launched at the Advances in Genome Biology and Technology (AGBT) 23rd General Meeting, currently taking place in Florida, US.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The Max Read Kits are designed to match the format of 10x Genomics assays and expected to boost the G4’s potential output to 3.2 billion reads per run on a single cell sequencing benchtop system.

This would provide users with the flexibility to sequence four, eight, 12 or 16 samples per run, with each in its own lane.

The company is planning to price the sequencing kits at $1 per million reads. It will provide 800 million reads per flow cell with an 80%-90% Q30 quality.

Singular Genomics chairman and CEO Drew Spaventa said: “We believe the combination of speed, flexibility, cost and power that the Max Read Kits provide will firmly establish the G4 as the leading benchtop system for customers running single cell applications.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“We look forward to sharing data at AGBT and to begin shipping to our customers in the second quarter of this year.”

Quality specifications for the G4 platform, including the F2 and F3 flow cells, have also been increased to 80%-90% Q30 quality.

Furthermore, the company increased the throughput range of the F2 and F3 cells to up to 250 million and up to 450 million reads, respectively.

Spaventa added: “We have seen consistent improvement on the throughput of our flow cells and, for certain applications, we are now achieving up to 1.8 billion reads per run on the F3 flow cells.

“We’ve been especially pleased with the quality of data coming from our F3 flow cells and are excited to start sending these to select customers later this month.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact